Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCaPE-CMD: CLBS16 in Coronary Microvascular Dysfunction
NCT03508609Phase 2Completed
- Sponsor
- Lisata Therapeutics
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD34+ cells in Coronary Microvascular Dysfunction (CMD), sponsored by Lisata Therapeutics. Started Apr 2018; status: completed.
02
Drugs
autologous CD34+ cells
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT03508609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508609.